NEW YORK, Aug. 25, 2020 /PRNewswire/ -- Seelos
Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage
biopharmaceutical company focused on the development of therapies
for central nervous system disorders and rare diseases, today
announced it has been granted Orphan Drug Designation (ODD) for
SLS-005 in mucopolysaccharidosis type III (MPS III), Sanfilippo
syndrome, from the European Medicines Agency (EMA).
To date, SLS-005 has been granted Orphan Drug Designation in the
US and Europe for Sanfilippo
syndrome, Spinocerebellar Ataxia Type 3 (SCA3) and Oculopharyngeal
Muscular Dystrophy (OPMD) as well as Fast Track designation for
OPMD.
Contact Information:
Anthony Marciano
Head of Corporate Communications
Seelos Therapeutics, Inc. (Nasdaq: SEEL)
300 Park Ave., 12th Fl
New York, NY 10022
(646) 293-2136
anthony.marciano@seelostx.com
https://seelostherapeutics.com/
https://twitter.com/seelostx
https://www.linkedin.com/company/seelos
View original
content:http://www.prnewswire.com/news-releases/seelos-therapeutics-receives-european-orphan-drug-designation-for-sls-005-trehalose-in-sanfilippo-syndrome-301117916.html
SOURCE Seelos Therapeutics, Inc.